● Recruiting

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

Condition: Head and Neck Squamous Cell Carcinoma · Squamous Cell Carcinoma of Anal Canal · Colorectal Cancer · Sponsor: Bicara Therapeutics

PhasePhase 1

Planned participants292

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors.

This description comes directly from the study's public registry record.

Talk to the study team

David Bohr · 6178000335 · info@bicara.com

Always discuss trial participation with your own doctor first.

Locations (20)

Moores Cancer Center UC San Diego Health	La Jolla, California, United States	Recruiting
Keck School of Medicine of USC	Los Angeles, California, United States	Recruiting
UCLA	Los Angeles, California, United States	Recruiting
University of California, Davis Comprehensive Cancer Center	Sacramento, California, United States	Recruiting
H. Lee Moffitt Cancer Center and Research Institute, Inc	Tampa, Florida, United States	Recruiting
Dana Farber/Partners Cancer Care Inc	Boston, Massachusetts, United States	Recruiting
Memorial Sloan Kettering	New York, New York, United States	Recruiting
Columbia University Herbert Irving Comprehensive Cancer Center	New York, New York, United States	Recruiting
Levine Cancer Institute	Charlotte, North Carolina, United States	Recruiting
Cleveland Clinic	Cleveland, Ohio, United States	Recruiting
UPMC Hillman Cancer Center	Pittsburgh, Pennsylvania, United States	Recruiting
Rhode Island Hospital	Providence, Rhode Island, United States	Recruiting

+ 8 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04429542